GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Equity-to-Asset

Ocumension Therapeutics (HKSE:01477) Equity-to-Asset : 0.89 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ocumension Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,193.8 Mil. Ocumension Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was HK$3,577.8 Mil. Therefore, Ocumension Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.89.

The historical rank and industry rank for Ocumension Therapeutics's Equity-to-Asset or its related term are showing as below:

HKSE:01477' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.68   Med: 0.9   Max: 0.96
Current: 0.89

During the past 6 years, the highest Equity to Asset Ratio of Ocumension Therapeutics was 0.96. The lowest was -8.68. And the median was 0.90.

HKSE:01477's Equity-to-Asset is ranked better than
83.52% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:01477: 0.89

Ocumension Therapeutics Equity-to-Asset Historical Data

The historical data trend for Ocumension Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Equity-to-Asset Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -1.60 0.96 0.93 0.90 0.89

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.93 0.90 0.90 0.92 0.89

Competitive Comparison of Ocumension Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Ocumension Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's Equity-to-Asset falls into.



Ocumension Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ocumension Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3193.799/3577.75
=0.89

Ocumension Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3193.799/3577.75
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (HKSE:01477) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ocumension Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Liu Ye 2101 Beneficial owner
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Chen Ziqing 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Boyu Capital Fund Iv, L.p 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines